news
FDA accepts lixisenatide NDA for review
29 September 2015 | By Victoria White
The NDA submission for lixisenatide is based on results from the GetGoal clinical programme and includes findings from the recently-completed ELIXA study...
List view / Grid view
Diabetes
news
Novo Nordisk completes second Phase 3a trial with semaglutide
25 September 2015 | By Victoria White
The trial investigated the efficacy and safety of semaglutide compared with exenatide in 813 people with type 2 diabetes...
news
Xultophy trial shows improvements in patient-reported outcomes
17 September 2015 | By Victoria White
The DUAL V trial evaluated the efficacy and safety of Xultophy compared to insulin glargine U100 in adults with type 2 diabetes...
news
Open dialogue could improve type 2 diabetes management
16 September 2015 | By Victoria White
Results from a new study showed different perceptions of control among physicians and patients that may lead to suboptimal type 2 diabetes management...
news
Liraglutide provides greater blood sugar reduction than lixisenatide in new trial
16 September 2015 | By Victoria White
Findings from the LIRA-LIXI trial have demonstrated a significantly greater reduction in blood sugar for liraglutide compared to lixisenatide in type 2 diabetes...
news
Abasaglar provides similar safety and efficacy to Lantus
15 September 2015 | By Victoria White
Data from secondary analyses of Phase III trials show Abasaglar (insulin glargine) demonstrated safety and efficacy outcomes similar to Lantus in diabetes...
news
Tresiba U200 delivers lower rates of hypoglycaemia
15 September 2015 | By Victoria White
Data show that Tresiba U200 significantly lowers both rates of hypoglycaemia and mean fasting blood glucose compared to insulin glargine U100 in patients with type 2 diabetes...
news
Early response to Saxenda predicts improvements in weight loss
15 September 2015 | By Victoria White
Not only are Saxenda 'early responders' more likely to achieve greater weight loss, they are also more likely to experience greater improvements in cardiometabolic risk factors...
news
Positive top-line results in second LixiLan Phase III study
14 September 2015 | By Victoria White
The fixed-ratio combination of insulin glargine and lixisenatide, a GLP-1 receptor agonist, demonstrated statistically superior reduction in HbA1c compared with insulin glargine alone...
news
TECOS analysis adds heart failure data for sitagliptin
2 September 2015 | By Victoria White
New TECOS study findings have shown that patients with type-2 diabetes can safely take sitagliptin without an increased risk of cardiovascular complications...
news
Synjardy tablets receive FDA approval for adults with type 2 diabetes
27 August 2015 | By Nick Jackson
Synjardy approval was based on multiple clinical trials showing reductions in blood glucose versus placebo...
news
Disappointing results for liraglutide in type 1 diabetes
25 August 2015 | By Victoria White
Novo Nordisk has announced headline results from the final Phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes...
news
Jardiance demonstrates CV risk reduction in type 2 diabetes
20 August 2015 | By Victoria White
Boehringer Ingelheim and Lilly have announced positive top-line results from a clinical study investigating cardiovascular (CV) outcomes for Jardiance...
news
Diabetes cases soar in the UK
17 August 2015 | By Victoria White
The number of people living with diabetes in the UK has soared by nearly 60% in a decade, according to a new analysis by Diabetes UK...
news
Sanofi’s Toujeo now available in the UK
4 August 2015 | By Victoria White
Toujeo is now available in the UK, providing another option for adults with type 1 and type 2 diabetes mellitus to help manage their condition...
